A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis

Primary focal segmental glomerulosclerosis (FSGS) is a disease with poor prognosis and high unmet therapeutic need. Here, we evaluated the safety and pharmacokinetics of single-dose infusions of fresolimumab, a human monoclonal antibody that inactivates all forms of transforming growth factor-β (TGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Trachtman, Howard, Fervenza, Fernando C, Gipson, Debbie S, Heering, Peter, Jayne, David R W, Peters, Harm, Rota, Stefano, Remuzzi, Giuseppe, Rump, L Christian, Sellin, Lorenz K, Heaton, Jeremy P W, Streisand, James B, Hard, Marjie L, Ledbetter, Steven R, Vincenti, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257033/
https://www.ncbi.nlm.nih.gov/pubmed/21368745
http://dx.doi.org/10.1038/ki.2011.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257033/
https://www.ncbi.nlm.nih.gov/pubmed/21368745
http://dx.doi.org/10.1038/ki.2011.33

Ejemplares similares